H. Ralph Snodgrass, PRES./CHIEF SCIENTIFIC OFFICER at VistaGen Therapeutics, Inc. (VTGN), bought 15,000 shares at $0.34 ($5K) on 2019-11-20, disclosed to the SEC on 2019-11-21.
Open-market purchase of $5k VTGN by PRES./CHIEF SCIENTIFIC OFFICER. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.